Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：0
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [11] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [12] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Mitova, R.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [13] The prognostic impact of BMI in patients with HR+/HER2-advanced breast cancer: a study of the SONABRE registry
    Lammers, Senna W. M.
    Thurisch, Hannah
    Vriens, Ingeborg J. H.
    Meegdes, Marissa
    Engelen, Sanne M. E.
    Erdkamp, Frans L. G.
    Dercksen, M. Wouter
    Vriens, Birgit E. P. J.
    Aaldering, Kirsten N. A.
    Pepels, Manon J. A. E.
    van de Winkel, Linda M. H.
    Peters, Natascha A. J. B.
    Tol, Jolien
    Heijns, Joan B.
    van de Wouw, Agnes J.
    Teeuwen, Nathalie J. A.
    Geurts, Sandra M. E.
    Tjan-Heijnen, Vivianne C. G.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (02) : 339 - 349
  • [14] Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Barriga, Susana
    Lin, Yong
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [15] Prognostic factors associated with clinical outcomes in HR+, HER2-Advanced Breast Cancer (ABC) - Systematic Literature Review (SLR)
    Kuemmel, S.
    Carter, Cuyun G.
    Stenger, K.
    Mohanty, M.
    Chong, A. L.
    Basa, P.
    Singuru, S.
    Singh, S.
    Tongbram, V
    Guarneri, V
    Tolaney, S. M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 160 - 160
  • [16] HR+/HER2-Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
    Jerzak, Katarzyna J.
    Bouganim, Nathaniel
    Brezden-Masley, Christine
    Edwards, Scott
    Gelmon, Karen
    Henning, Jan-Willem
    Hilton, John F.
    Sehdev, Sandeep
    CURRENT ONCOLOGY, 2023, 30 (06) : 5425 - 5447
  • [17] Outcomes of male patients with HR+/HER2-advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Blum, Joanne L.
    Dicristo, Caroline
    Gordon, David
    Karuturi, Meghan S.
    Oubre, David
    Jepsen, Erin
    Cuevas, Juan
    Lakhanpal, Shailendra
    Montelongo, Monica Z.
    Zhang, Zhe
    Cappelleri, Joseph C.
    Wang, Yao
    Tripathy, Debu
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 203 (03) : 463 - 475
  • [18] PATIENT REPORTED TREATMENT SATISFACTION WITH PALBOCICLIB COMBINATION THERAPIES FOR HR+/HER2-ADVANCED OR METASTATIC BREAST CANCER IN MULTIPLE COUNTRIES
    Mitra, D.
    Darden, C.
    McSorley, D.
    Davis, K.
    Band, J.
    Iyer, S.
    VALUE IN HEALTH, 2018, 21 : S36 - S36
  • [19] Palbociclib versus abemaciclib in HR+/HER2-advanced breast cancer: an indirect comparison of patient-reported end points
    Law, Ernest
    Gavanji, Roya
    Walsh, Sarah
    Haltner, Anja
    McTavish, Rebecca
    Cameron, Chris
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (02) : 109 - 120
  • [20] Palbociclib Plus Fulvestrant Maintains Long-Term Overall Survival Benefit in HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S5 - S6
12345